Clinical trials
Phase 1 Sjogren's Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 12 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 15 |
| Not yet recruiting | 8 |
| Completed | 8 |
| Withdrawn | 2 |
| Suspended | 2 |
| Terminated | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nanjing Bioheng Biotech Co., Ltd. | 3 |
| Amgen | 2 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 |
| Guangdong ProCapZoom Biosciences Co., Ltd. | 2 |
| Antengene Biologics Limited | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Beijing Boren Hospital | 1 |
| Bristol-Myers Squibb | 1 |
| Candid Therapeutics | 1 |
| Children's Hospital of Fudan University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sjogren's Syndrome | 39 |
| Lupus Erythematosus, Systemic | 23 |
| Scleroderma, Systemic | 18 |
| Myositis | 15 |
| Autoimmune Diseases | 11 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 10 |
| Arthritis, Rheumatoid | 7 |
| Antiphospholipid Syndrome | 5 |
| Dermatomyositis | 5 |
| Dry Eye Syndromes | 3 |
Trials
Showing 26 to 39 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.